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KADAR JANGKA HAJAT BUAH PINGGANG DAN FAKTOR-FAKTOR 
PROGNOSTIK DALAM KALANGAN PESAKIT BUAH PINGGANG KRONIK DI 
HOSPITAL UNIVERSITI SAINS MALAYSIA. 
ABSTRAK 
 
Pengenalan: Penyakit buah pinggang tahap terakhir dalam kalangan pesakit buah 
pinggang kronik merupakan satu beban yang berat kepada pesakit, keluarga, dan 
sistem penjagaan kesihatan. Objektif: Objektif kajian adalah untuk mengetahui 
tempoh hayat buah pinggang dalam kalangan pesakit buah pinggang kronik di Hospital 
USM serta mengenalpasti factor-faktor prognostik yang mempengaruhi jangka hayat 
buah pinggang. Kaedah: Kajian kohort retrospektif dijalankan melibatkan 247 orang 
pesakit buah pinggang kronik di Hospital USM Kelantan bermula pada Januari 2005 
hingga Disember 2015. Semua pesakit yang memenuhi kriteria yang perlu telah 
dimasukkan ke dalam kajian ini. Data pesakit diperolehi melalui rekod perubatan dan 
tempoh jangka hayat buah pinggang berdasarkan tempoh pesakit disahkan 
menghidapi penyakit buah pinggang kronik sehingga buah pinggang tahap terakhir. 
Analisis „Kaplan-Meier‟ dan „Cox proportional hazard regression‟ telah digunakan 
dalam analisis statistik. Keputusan: Secara kesuluruhan, kadar jangka hayat buah 
pinggang dari tempoh disahkan sehinnga tahap akhir buah pinggang adalah 26 bulan. 
Factor-faktor prognostik yang mempegaruhi jangka hayat buah pinggang dalam 
kalangan pesakit buah pinggang kronik adalah GFR (Nisbah bahaya selaras (HR)= 
0.96, 95% Selang keyakinan: 0.98,0.99; nilai p<0.001), status merokok (Nisbah bahaya 
selaras= 2.19, 95% Selang keyakinan: 1.53, 3.13; nilai p=0.042), comorbid penyakit 
kolestrol (Nisbah bahaya selaras=1.87, 95% Selang keyakinan: 1.34,2.60; nilai p = 
0.005), analgesik (Nisbah bahaya selaras= 1.87, 95% Selang keyakinan: 1.21,2.88; 
nilai p = 0.015), gangguan GI berfungsi (Nisbah bahaya selaras=1.42, 95 % Selang 
keyakinan: 1.07,2.01; nilai p = 0.016), ejen merendahkan lipid (Nisbah bahaya selaras= 
1.41, 95% Selang keyakinan: 1.02,1.97; nilai p = 0.039), kortikosteroid (Nisbah bahaya 
xv 
 
selaras= 2.10, 95% Selang keyakinan: 1.25,3.55; nilai p = 0.005 ), urea (Nisbah 
bahaya selaras= 1.03, 95% Selang keyakinan: 1.01,1.05; nilai p <0.001), dan 
kreatinina (Nisbah bahaya selaras= 0.98, 95% Selang keyakinan: 0.97,0.99; nilai p = 
0.005). Kesimpulan: Jangka hayat bauh pinggang dalam kalangan pesakit buah 
pinggang kronik dalam kajian ini sangat cepat iaitu dalam masa 26 bulan. Factor-faktor 
prognostik seperti takat GFR, status merokok, comorbid penyakit kolestrol, analgesic,  
gangguan GI berfungsi, ejen merendahkan lipid, kortikosteroid, urea dan kreatinina 
mempengaruhi buah pinggang dalam kalangan pesakit buah pinggang kronik.  
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RENAL SURVIVAL AND ITS PROGNOSTIC FACTORS IN CHRONIC KIDNEY 
DISEASE (CKD) PATIENTS IN HOSPITAL UNIVERSITI SAINS MALAYSIA, 
KELANTAN 
 
ABSTRACT 
 
 
Introduction: End Stage of Renal Disease (ESRD) in Chronic Kidney Disease (CKD) 
patients represents a heavy burden for patients, families, and health care systems. 
Objectives: The objectives of this study were to determine the renal survival time of 
CKD patients at Hospital USM and to identify the prognostic factors that influence the 
renal survival of patients. Methodology: A retrospective cohort study was conducted 
involving 247 CKD patients at Hospital USM, Kelantan from January 2005 until 
December 2015. All patients who fulfilled the criteria were included in the study. The 
medical record were reviewed and the renal survival time based on the time of the first 
date of diagnosis with CKD until the the first date of diagnosis with ESRD or received 
dialysis. The Kaplan-Meier and Cox proportional hazard regression analyses were 
used in the statistical analysis. Results: Overall renal survival time of CKD patients 
was 26 months. The significant prognostic factors that influence the renal survival of 
CKD patients were GFR (adjusted hazard ratio (HR)=0.96, 95% confidence interval 
(CI): 0.98,0.99; p value <0.001), smoking status (adjusted HR=2.19, 95% CI: 1.53, 
3.13; p value=0.042), comorbid hyperlipidemia (adjusted HR=1.87, 95% CI: 1.34,2.60; 
p value =0.005), analgesics (adjusted HR=1.87, 95% CI: 1.21,2.88; p value =0.015), 
functional GI disorder (adjusted HR=1.42, 95% CI:1.07,2.01; p value =0.016), lipid 
lowering agents (adjusted HR=1.41, 95% CI: 1.02,1.97; p value=0.039), corticosteroid 
(adjusted HR=2.10, 95% CI: 1.25,3.55; p value =0.005), urea (adjusted HR=1.03, 95% 
CI: 1.01,1.05; p value <0.001), and creatinine (adjusted HR=0.99, 95% CI: 0.98,1.00; p 
value =0.005). Conclusion: The medium renal survival time of CKD patients in this 
xvii 
 
study very fast within 26 month. The prognostic factors of renal survival identified were 
GFR level, smoking status, comorbid hyperlipidemia, analgesics, lipid lowering agents, 
functional GI disorder, corticosteroid drugs, urea and creatinine are significant to renal 
survival among CKD patients in Hospital USM. Thus, the clinician can change the 
clinical management by focus on the factors and slow the progression to ESRD. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Epidemiology of CKD 
 
Chronic kidney disease (CKD) is defined as abnormalities of kidney structure or 
function, present for more than three months, with the implications for health. CKD is 
classified based on its cause, GFR category and albuminuria category (Levin and 
Stevens, 2013) 
 
The incidence and prevalence of CKD were increasing (Rowa Al-Ramahi, 2012). The 
estimated prevalence of CKD in the US was 16.8% (CPG Secretariat, 2011). CKD is 
one of the most diseases, leading to death among adults in Malaysia (CPG Secretariat, 
2011) 
 
According to Li et al. (2001), the global epidemic of CKD has posed a main public 
health problem, not only in high-income countries but also in Asia. In Asia, the 
prevalence ranged from 12.1% to 17.5% (CPG Secretariat, 2011). The estimated 
prevalence of CKD was 13% in a large sample of 13 295 adults in China, a cohort of 
574 024 adults in Japan showed the same prevalence of CKD was as reported in 
China (Li et al., 2001). The overall prevalence of CKD in West Malaysia was 9.07% 
(Hooi et al., 2013) 
 
According to Wulandari et al. (2013), CKD patients diagnosed in Hospital Universiti 
Sains Malaysia were the end-stage renal failure which was the most frequency disease 
diagnosed (36.8%), and the second frequency was CKD stage IV (18.4%). With 18 
million populations in Malaysia, the number cases of kidney failure case per year were 
1800 and 100 cases in 2010 were ESRD (Wulandari et al., 2013). In Scotland, the 
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increasing of the prevalence of diabetes is the most cause probable to a significant 
increase in patients with end-stage renal disease (ESRD) requiring renal replacement 
therapy (RRT). The incidence of new patients on RRT in 2011 was 96 per million 
population (pmp) with 24% of patients with diabetes as their primary renal diagnosis 
between 2007 and 2011 (S. Bell et al., 2014). 
 
1.2 Burden of CKD 
 
CKD contribute to a major challenge for the healthcare systems around the world. 
Patients with kidney disease have implications for their individual health which can 
occur abruptly, and either resolved or became more chronic. The growing number of 
ESRD places an enormous human, economic and social burden on the healthcare 
system (Kerr et al., 2012).  The prevalence of CKD by stages 1, 2, 3, 4, and 5 were 
4.16%, 2.05%, 2.26%, 0.24%, and 0.36%, respectively (Hooi et al., 2013). The 
prevalence of stages 3 and 4 CKD at baseline was 4.4% and 0.1% of patients who 
progress to ESRD (Stein I. Hallan et al., 2009). Furthermore, according to management 
CKD in adults books reported the incidence and prevalence of patients with ESRD on 
dialysis had increased from 88 and 325 per million population (pmp) respectively in 
2001 to 170 and 762 pmp respectively in 2009 in Malaysia (CPG Secretariat, 2011). 
 
Kerr et al. (2012) also reported the definition of direct costs were from health care 
provided explicitly for or because of CKD while indirect costs are defined as those 
rising from non-renal conditions for which CKD carries increased hazard. For non-renal 
conditions, costs were estimated only for „excess‟ events, above the level probable for 
a matched population without CKD. In the year 2009 to 2010, the estimated 
expenditure on CKD  spending on renal problems at £1.64 based on NHS Programmed 
Budgeting data (Kerr et al., 2012). Primary concern of ESRD among the elderly and 
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diabetics is the increasing the cost of care in a treatment modality that already 
consumes a disproportionate share of the health care budget (White et al., 2008). In 
Malaysia, accordingly to CPG Secretariat (2011), in an economic evaluation of Ministry 
of Health dialysis centers in Malaysia, the cost of dialysis and erythropoietin was 
RM2,500 per month.  
 
Adult patients who experienced episodes of AKI were leading to more rapid 
progression of CKD (Stuart et al., 2010). In 2009, the United States Renal Data System 
Report revealed that adults patient with an acute kidney injury (AKI) episode during 
hospitalization have about ten times greater risk of progressing to ESRD by twelve 
months than patients who did not experience with AKI (Stuart et al., 2010). Social 
burden reported by CKD patients were cognitive impairment, dementia, sleep 
disturbance, pain, and emotional and physical dysfunction (Braun et al., 2012). 
 
In Malaysia, there were 27,572 patients on RRT by the end of 2011, which places a 
large burden on the health-care budget and the prevalence rate of 966 per million 
population (Nagata et al., 2010). There has been increasing trend in dialysis provision 
for ESRD in Malaysia from 96 per million population in 2002 to 182 per million 
population in 2011(Hooi et al., 2013). The donation of RRT in developing economies 
was limited by lack of financial and other resources. Thus, there are no national 
reimbursement policies for RRT in many countries in Southeast Asia of Singapore, 
Malaysia, Thailand, and Indonesia where have accepted a plan of encouraging public-
private partnerships to increase the RRT rates in their respective countries (Morad et 
al., 2015) 
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1.3 Problem Statement 
 
CKD and ESRD are currently considered as major health burdens. The Kidney Disease 
Improving Global Outcome (KDIGO) stated that the complications of CKD affect all 
organ systems. Kidney failure leads to the commonly recognized symptoms of uremia 
(Levin and Stevens, 2013) 
 
According to last decades, therapeutic advances to slow down the progression of CKD 
have largely unsuccessful due to several possible reasons such as the lack of profound 
understanding of the pathophysiology of chronic renal damage, an inadequate 
characterization of molecular mechanisms of currently approved therapies such as 
renin angiotensin aldosterone-system (RAAS) blockade, the unclear biochemical 
property needs required for novel therapeutic approaches, the missing quantity and 
quality of clinical trials in the nephrology field and the main reasons is the absence of 
prognostic renal biomarkers that reflect the severity of the structural organ damage and 
predict ESRD. Currently, CKD remains without approved treatment underlying the need 
for new treatment to successfully address this high unmet medical need. (Formentini et 
al., 2012) 
 
1.4 Justification of Study  
 
Many studies have been done in other countries include Malaysia to determine the 
survival of CKD, but only a few studies had been published from Malaysia. Although 
many studies had been done about CKD, there is no well-documented study on renal 
survival in different CKD staging, from diagnosis with CKD at different stages to the 
ESRD. A study about the prognostic factors of kidney disorders at the Hospital 
Universiti Sains Malaysia had been conducted by Wulandari et al. (2013). However, 
this study did not investigate the renal survival of CKD patients. 
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The majority of studies explored the risk factors or prognostic factors among CKD 
patients. However, there is not much information on the associated of factors of renal 
survival of CKD patients in Malaysia. Thus, this study will provide some beneficial 
information regarding renal survival and prognostic factors prognostic factors in CKD in 
Hospital USM, Kubang Kerian, Kelantan. The research findings of this study 
highlighted the importance of knowing the time progression of CKD staging. 
 
This study had come up with renal survival which more prognostic factors had been 
considered. The results of this study were expected to give some positive impact to 
know the time progression of CKD staging from stage to stage. Early recognition and 
intervention are essential to slowing disease progression, maintaining the quality of life, 
and improving outcomes. Physicians have the opportunity to screen the time 
progression of CKD patient from diagnosis to ESRD, identify the factors that are 
influencing the CKD progression. This study can help alert physicians to need 
interventions, and help slow disease progression. 
 
1.5 Research Questions 
 
1. What are the profiles of renal survival of chronic kidney disease (CKD) patients 
in Hospital Universiti Sains Malaysia? 
2. What is the renal survival time of chronic kidney disease (CKD) patients in 
Hospital Universiti Sains Malaysia? 
3. What are the prognostic factors of renal survival of chronic kidney disease 
(CKD) patients in Hospital Universiti Sains Malaysia? 
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1.6 General Objective 
 
To determine renal survival time and its prognostic factors in CKD patients in 
Hospital Universiti Sains Malaysia. 
1.6.1 Specific Objectives 
 
1. To determine socio demographics and premobid conditions of chronic kidney 
disease (CKD) patients in Hospital Universiti Sains Malaysia. 
2. To determine the renal survival time of chronic kidney disease (CKD) patients in 
Hospital Universiti Sains Malaysia  
3. To identify the prognostic factors of renal survival of chronic kidney disease 
(CKD) patients in Hospital Universiti Sains Malaysia 
 
1.7 Hypothesis  
 
1. The prognostic factors of renal survival of chronic kidney disease (CKD) 
patients in Hospital Universiti Sains Malaysia are socio-demographic 
characteristics, clinical characteristics, laboratory parameters and treatment 
characteristics.  
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CHAPTER 2 
 LITERATURE REVIEW 
 
Literature search strategies were used to identify the relevant information and articles 
of the area of interest. The literature searches were used by using phrase searching 
such as citation search and Boolean operators. Several phases had been used in 
phase searching include “renal survival among CKD”, “prognostic factors with renal 
survival”, and “progression of CKD in Malaysia”. For keywords used were “prognostic 
factors AND renal survival” and “renal survival AND progression of CKD AND chronic 
kidney disease”. For citation search, author‟s name and title of article were used. The 
search engines used were PubMed, Google Scholar and Science Direct. Related 
articles needed were imported to Endnote library. 
 
2.1 Progression of CKD patients 
 
2.1.1  Staging of CKD 
 
Renal survival time was calculated from the time to progression from onset of the date 
of diagnosed of CKD to the date of confirmed end stage of renal disease (ESRD) (Tsai 
et al., 2014). If all patients who were found to have CKD stages 1 through 4 were 
referred to nephrologists, then it would place under specialist care 50.2% of all patients 
in the general population and would progress to ESRD within the next 10.3 year 
(Hallan et al., 2009). Moreover, the prevalence of CKD stages 3 and 4 at baseline 
characteristics was 4.4% and 0.1%  and prevalence of patients who did not progress to 
ESRD 46.0%  whereas patients who did progress to ESRD was 23.4% (Hallan et al., 
2009).  
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Differences in CKD stages also raise important questions concerning the identification 
of risk factors associated with progression of CKD to ESRD. Among these is the 
observation that prevalence rates of stage 3 CKD are now 10 to 20 times more than 
prevalence rates of stages 4 and 5 CKD (Winearls and Glassock, 2009). 
 
Table 2.1 shows the description of CKD staging based on (National Kidney 
Foundation-Kidney Disease Outcomes Quality Initiatives) NKF-KDOQI classification. 
The classification based on GFR (level of kidney function) factor, pathological changes 
(kidney damage) factor and the presence of the abnormality for at least three months. 
From KDOQI, the kidney damage was defined when persistent microalbuminuria, 
persistent proteinuria, persistent hematuria, radiological evidence of structural 
abnormalities of the kidneys and biopsy-proven glomerulonephritis (CPG Secretariat, 
2011). 
 
Table 2.1 Staging of Chronic Kidney Disease 
Stage GFR 
(ml/min/1.73m²) 
Description 
1 
 
2 
 
3A 
3B 
 
4 
5 
≥90 
 
60-89 
 
45-59 
30-44 
 
15-29 
<15 
Normal or increased GFR, with other evidence of 
kidney damage 
Slight decrease in GFR, with other evidence of 
kidney damage 
 
Moderate decrease in GFR, with other evidence of 
kidney damage 
 
Severe decrease in GFR, with other evidence of 
kidney damage 
Establish renal failure 
        (CPG Secretariat, 2011) 
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2.1.2 GFR level 
 
In multivariable survival analysis, estimated GFR (eGFR) was independently and 
strongly associated with progression to ESRD with hazard ratios for eGFR 45-59, 30-
44, and 15-29 ml/min per 1.73 m2 were 6.7, 18.8, and 65.7, respectively and P < 0.001 
for all category of eGFR (Hallan et al., 2009). Furthermore, time-dependent receiver 
operating characteristic analyses showed that considering for both urinary 
albumin/creatinine ratio and eGFR substantially improved diagnostic accuracy. Referral 
based on current stages 3 to 4 CKD (eGFR 15 to 59 ml/min per 1.73 m2) would include 
4.7% of the general population and recognize 69.4% of all individuals progressing to 
ESRD. (Hallan et al., 2009).  
 
Currently, Formentini et al. (2012) reported accepted end points for  ESRD among  
CKD patients were defined as GFR <15 mL/min per 1.73 m2 or initiation of RRT were 
impractical for clinical development. The reason is most of CKD patients progress 
relatively slowly, and long follow-up would be needed for a CKD study before reaching 
ESRD and second reasons based on renal patients who start RRT with a much lower 
progress compare to patients who postpone their starting appointment of RRT 
(Formentini et al., 2012) 
 
According to Cox regression analysis by Hallan et al. (2009), showed that within each 
albumin to creatinine ratio (ACR) category, lower eGFR categories were associated 
with a higher risk. Similarly with progressively higher ACR categories were associated 
with a progressively higher risk within each eGFR category. Steadily, results of the 
Modified Diet in Renal Disease (MDRD) study from Peterson et al. (1995) showed that 
reduction of proteinuria achieved by intensified BP control was associated with lower 
GFR decline. 
10 
 
 
 Among multiethnic Asian population, there is a consensus on the accuracy in 
assessing the CKD by using the MDRD and C-G formula (Chin and Mooi, 2012). 
According to Carroll (2006), stated that the best available method to estimate GFR is 
the equation from the Modification of Diet in Renal Disease (MDRD) study. In clinical 
practice, the MDRD equation has several advantages where the formula was accurate 
when compared to GFRs measured with nuclear medicine techniques, which are 
considered the gold standard for measuring kidney function, though they are rarely 
available, and are difficult to perform (Carroll, 2006). The formula for MDRD eGFR is 
calculated in ml/mim/1.73m2 : 175 x (Serum Creatinine/ 88.4)1.154 x (Age) -0.203 x (0.742 if 
female) (CPG Secretariat, 2011). 
 
2.1.3 NSAID Usage as Progression of CKD 
 
Consumption of non-steroidal anti-inflammatory drugs (NSAIDs) is well-known, and 
they are frequently prescribed and can be easily obtained over the counter as 
analgesics. The examples of NSAIDs are diclofenac, ibuprofen, and indomethacin, and 
selective COX-2 inhibitors. The previous study showed that use of NSAIDs has to have 
adverse effects on renal function and prior studies have associated both NSAIDs and a 
subclass, cyclooxygenase-2 (COX-2) inhibitors, to an increased risk of kidney disease 
(Patel et al., 2012). 
 
 High-cumulative NSAID exposure was significantly associated with an increased risk 
of the faster of CKD progression (Gooch et al., 2007).The previous study also found 
that those on regular aspirin with stage 4–5 CKD had a slower rate of disease 
progression per year (Nderitu et al., 2013). Nderitu et al. (2013) found that those with 
stage 3B CKD was significantly associated with NSAID use in both gender. The 
incidence rate of stage 3B CKD was 58.46 and 42.02 per 10 000 person years for 
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women and men (Nderitu et al., 2013). NSAIDs and selective COX-2 inhibitors, only be 
given with monitoring of the serum creatinine level  as the drugs can lead to further of 
permanent renal damage (Dtsch Arztebl, 2010) 
High dose NSAID used may significantly increase the risk of accelerated renal function 
decline by 26% (Nderitu et al., 2013). Whereas, a study from Yarger et al. (2011) 
reported the high-dose NSAID users made up just 4.2% of the total sample population 
and only 13.4% of these patients had accelerated CKD progression.  
 
2.1.4  CKD progression by Socio-demographic Characteristics 
 
 
According to Tsai et al. (2014), from 2831 patients with ESRD, the younger age below 
than 30 years were initially identified. The incidence rates of ESRD progressively 
increased with age, except for a small peak in infants (Tsai et al., 2014).  
 
According to multivariate analysis, variables younger age, male gender, higher blood 
pressure, not on ACEIs or ARBs, lower haemoglobin, higher proteinuria and lower 
relative lymphocyte count (RLC) were give significant results with associated with 
progression to ESRD after adjustment (Mi and Woo, 2014). 
 
The survival time were divided into early and late start groups by the median estimated 
creatinine clearance (eCCr) for all patients at initiation of dialysis, which was 8.3 
ml/min. Patients who started dialysis shows a lower estimated creatinine clearance 
tended to survive longer. The model retained significance when gender, age, weight, 
presence of diabetes, mode of first dialysis, initial dialysis access, hemoglobin, serum 
albumin, blood leukocyte count, and eCCr at the start of dialysis was controlled 
(Traynor et al., 2002). 
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In previous studies, smoking had previously been associated with progression of CKD.  
The prevalence of diabetic nephropathy was highly significantly among heavy smokers 
which defined as more than ten cigarettes a day for more than one year compared than 
among non-heavy smokers (Telmer et al., 1984). Smoking also reported a significant 
associated with progression of ESRD by hazard ratio 1.56 and 95% CI 0.84 to 2.87 
compared for those non-smoker (Kim and Kim, 2014). Among diabetic patients 
smoking has been repeatedly confirmed as an independent risk factor for onset and 
progression of diabetic nephropathy. Moreover, insulin are dependent and independent 
diabetes mellitus the risk to develop microalbuminuria or proteinuria that substantially 
higher in smokers, and smoking also accelerates the rate of progression of diabetic 
nephropathy to end-stage renal failure (ESRF) (El Nahas and Bello, 2005). 
 
2.2 Median Survival of CKD patients 
 
Causes of ESRD from Tsai et al. (2014) study reported the most common causes of 
ESRD in the young population were glomerulonephropathy, followed by hypertension 
and genetic and metabolic diseases. The median time of overall renal survival was 0.8 
year (interquartile range, 0.7–3.5 years). Congenital anomalies of the kidney and 
urinary tract (CAKUT) had the longest progression time with median renal survival was 
16.0 years to ESRD, while glomerulonephropathy progressed more rapidly than in 
patients whose ESRD was due to diabetic nephropathy (median renal survival, 0.5 
versus 3.2 years). Among the glomerulonephropathy related cases of ESRD, HSP and 
SLE had longer renal survival time compared with other glomerulonephropathies with 
median renal survival time for HSP (3.1 years) compared than for SLE (2.7 years) and 
other glomerulonephropathies was 0.3 year (Tsai et al., 2014) 
 
The probability of reaching CKD stage 5 was estimated as 52% for ten years, where 
the most accurate model included eGFR, proteinuria at admission, and primary renal 
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disease. The probability of renal survival was estimated about 63% for patients in the 
low-risk group and 43% for the medium-risk group and all patients assigned to the 
high-risk group had CKD stage 5 with a p-value less than 0.001.The median renal 
survival was only 23 months with 95% CI, 13 to 45 months for patients with glomerular 
disease versus 122 months with  95% CI, 91.2 to 152.3  months for children with other 
primary diseases (Cerqueira et al., 2014). 
 
The median survival time in patients with aged <75 years was 69.6 months in RRT 
group with p-value <0.001, in the absence of high comorbidity and non-diabetics CKD 
patients. While, the medium survival time for older patients was 28.5 months with P-
value < 0.001.(Chandna et al., 2010).  
 
Among a total of 500 patients who had IgA-N therapy, based on time follow up, the 
renal survival from the time of apparent disease onset was 96.4% at 10 years, 84.5% 
at 15 years and 73.9% at 20 years (Yata et al., 2008). According to Kukla et al. (2008) 
that conducted a study about stage-to-stage progression based on baseline two group 
of CCR and eGFR, the median time of stage half-life according to CCR was 5.4 years 
whereas according to eGFR was 6 years. Study from Traynor et al. (2002), patients 
who started dialysis shows a lower estimated creatinine clearance (eCCr) tended to 
survive longer. A Cox proportional hazards model reported a significant inverse 
relationship between eCCr at start of dialysis and survival with hazard ratio 1.1 and  p-
value  0.02 (Traynor et al., 2002) 
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2.3  Prognostic Factors of Renal Survival of CKD patients 
 
2.3.1 Socio-demographic factors 
 
2.3.1.1  Age 
 
A study from Eriksen and Ingebretsen (2006), Cox proportional hazards regression 
analyses were found age, gender, and GFR significant result toward competing for 
renal failure and death. Furthermore, the interactions between these three variables 
were tested in the analyses, but none was found significant.  Older people with 
increased one year of aged were increased hazard risk in renal progression with two 
group of eGFR (eGFR ≥ 45 ml/min/1.73 m2 ; HR:1.11) and (eGFR < 45 ml/min/1.73 
m2; HR: 1.06) (Wu et al., 2013).  
 
According to study by Kim et al. (2014) with mean age at enrollment was 59 ± 12 years, 
and 191 (66 %) patients were male with mean eGFR was 37 ± 11 ml/(min 1.73 m2 ). 
The factor associated with increased progression to ESRD was younger age, with HR 
0.96 and 95 % CI 0.94 to 0.98. However, study from Eriksen and Ingebretsen (2006), 
showing that older patients are more likely to die than to develop ESRD in contrast to 
younger patients. 
 
2.3.1.2  Smoking Status 
 
Former and current-smokers less than 70 years of age at inclusion had significant 
multi-adjusted hazard ratios of 3.32 and 4.01 for kidney failure compared to those who 
never smoked (Hallan and Orth, 2011).   
Hallan and Orth (2011) reported that the prevalence of current smoking did not differ 
between genders, females (10.2 pack-years) had smoked less than men (15.8 pack-
years), and the number of kidney failure cases was lower in females than in men. The 
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effect of smoking on the risk of kidney failure was similar between women (HR=2.94) 
and men (HR=4.30), but did not reach statistical significance in women. Thus, this large 
population-based sample, this study found that smoking is a significant risk factor for 
future kidney failure (Hallan and Orth, 2011). 
Cigarette smoking has been known as a risk factor for the development and 
progression of chronic kidney disease (CKD) in community-based longitudinal cohort 
studies. Hazard ratio of Multivariate Cox proportional hazards models identified current 
smokers was HR, 2.03 (95% CI, 1.33-3.10)  as the primary outcome and number of 
cigarettes at kidney biopsy as significant predictors of the outcomes (Yamamoto et al., 
2010).  
 
2.3.2  Comorbidities  
 
One of the prognostic factors for CKD is hypertension that had been shown worldwide. 
In hypertension, glomerular filtration had been reported to decline more rapidly at a rate 
of 1.5 mL/ min per 1.73 m2 every year compared to those without hypertension whose 
decline at 0.75–1.00 mL/ min per 1.73 m2 every year with age of 40 years and above 
(Hanratty R et al., 2010). 
 
According to Meng and Ahmad (2011) , large studies showed that patients with 
hypertension had a significantly higher risk of developing CKD compared with 
normotensive patients. Besides that, hypertension may be a cause or consequence of 
renal failure. It accelerates the progression of renal disease and may lead to ESRD. 
 
High systolic blood pressure was shown to be significantly correlated to low GFR, 
which indirectly depicts the importance of optimising blood pressure control in CKD 
patients (p=0.001; r =-0.229). This result was supported by Marc A. Pohl et al. in 
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Irbesartan Diabetic Nephropathy Trial (IDNT), which also showed the presence of a 
direct relationship between control of systolic BP and adverse renal outcomes among 
type 2 diabetic nephropathy patients, independent of baseline renal function (Hamid et 
al., 2011). 
 
The major underlying disease of end-stage kidney failure throughout the world in both 
developed and developing nations is diabetes. It is the primary diagnosis causing 
kidney disease in 20-40 % of people starting treatment for ESRD (Atkins and Zimmet, 
2010). Diabetes is a common disease of CKD patients that requires aggressive 
management. HbA1C should be reduced to less than 7%, higher levels of HbA1C are 
associated with CKD progression (Carroll, 2006). 
 
In Malaysia, the number of diabetics has increased by almost 80 percent in the last ten 
year (Hamid et al., 2011). Furthermore, DM is a major cause contributed to CKD, which 
is contributing to 58% of new patients requiring dialysis in 2009 (Ong Loke Meng and 
Ghazali Ahmad, 2011). Commonly, Chronic kidney disease (CKD) can be found in up 
to 23% of patients with diabetes (Kerri L. Cavanaugh, 2007).  
 
According to Thomas et al. (2008), anaemia may be diagnosed in patients at different 
stage of CKD, and there is a strong correlation between the prevalence of anaemia and 
the severity of CKD.  Therefore, primary care providers play an important role in 
diagnosing and managing anaemia in CKD patients (Thomas et al., 2008). A study 
from Levin and Rocco (2006), defined CKD patient were related to anaemia when 
result of  haemoglobin levels less than 13.5 g/dL in men or 12 g/dL in women.  
 
The majority of enroled patients were in CKD stage 3 (65%), in stage 4 (31%) and in 
stage 5 (4%). The results from Cox Regression analyses, patients with persisting mild 
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anaemia and those with progressing anemia had a risk of ESRD that was about 80% 
higher than that of the patients with no anaemia (De Nicola et al., 2010) 
 
 
2.3.3  Biochemical parameters 
 
2.3.3.1   Proteinuria  
 
Trace amounts of protein in the urine are normal among CKD patients. However, 
persistently high levels of proteinuria are associated with progressive CKD. Patients 
with type 2 diabetes and hypertension were had a small amounts microalbuminuria are 
widely appreciated as a marker of “endothelial mischief”. In addition, all patients with 
even trace amounts of proteinuria should be considered candidates for cardiac stress 
testing, and further workup (Carroll, 2006). 
 
The prognostic factor of progression to ESRD among patients who had proteinuria 
during the first 6 months of follow-up was 3.7 fold times than that among patients who 
did not have proteinuria during the study period with significant p-value was 0.007, 
hazard ratio was 3.685 and 95 % confidence interval was 1.437–9.499 (Kim and Kim, 
2014). 
 
Proteinuria is an important risk factor for kidney failure and provides a means to identify 
patients at greatest risk. Halving proteinuria halves the kidney risk. Angiotensin 
receptor-blocking agent, such as irbesartan, should be regarded as an important 
therapeutic goal in renoprotective strategies since can reduced proteinuria. For each 
halving of proteinuria level between baseline and 12 months with treatment, risk for 
kidney failure was reduced by more than half (HR: 0.44; 95% CI: 0.40, 0.49; P < 0.001) 
(Atkins et al., 2005) 
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2.3.3.2  Uric Acid 
 
Both correlation results between serum uric acid level and level of GFR was inverse, 
significant for women (r=0.17; P=0.02) and men (r=0.22; P=.001). Whereas, the 
unadjusted HR results for uric acid level of Cox Regression analysis was 1.15 (95% CI: 
1.04-1.27; P-value: 0.009), and after adjustment for potential confounders, the HR was 
1.23 (95% CI, 1.09-1.39; P-value: 0.001). The only factors significantly associated with 
GFR decrease were uric acid level (Bellomo et al., 2010). Thus, according to Bellomo 
et al. (2010) study, the findings contributed to the demonstration of uric acid as an 
important risk factor for loss of kidney function. 
 
Greater uric acid levels were associated with older age, male, smoking status, greater 
BMI, greater prevalence of hypertension, diabetes, use of blood pressure medications, 
including diuretics, and ECG abnormalities according to Chonchol et al. (2007). 
Patients with an estimated GFR less than 60 mL/min/1.73 m2 increased more than 5 
times across uric acid quintiles .The multivariate adjustment, the odds of an estimated 
GFR less than 60 mL/min/ 1.73 m2 remained linearly associated with increasing 
quintiles of uric acid concentration . The model was repeated evaluating uric acid as a 
continuous variable after multivariate adjustment, 1 mg/dL (59 mol/L) increased in uric 
acid level, the odds of CKD increased by 1.71 (95% CI, 1.61 to 1.81) (Chonchol et al., 
2007) 
 
2.3.3.3  Blood Pressure 
 
There is a longitudinal association between achieved blood pressure (BP) and end-
stage renal disease (ESRD) among patients with chronic kidney disease (CKD) have 
not incorporated time-updated BP with appropriate covariate adjustment. The finding 
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indicated the time-updated SBP greater than 130 mm Hg was more strongly associated 
with CKD progression than analyses based on baseline SBP (Anderson et al., 2015).  
 
2.3.3.4  Relative Lymphocyte Count 
 
According to Kim et al. (2014), 105 of 288 patients (37 %) progressed to ESRD. 
Decreased absolute lymphocyte counts were associated with the accelerated rate of 
GFR decline in simple correlation analysis (r = 0.133; p = 0.024), indicating that 
lymphocyte count may be reflected CKD progression. When progression to ESRD was 
compared between patients with low or high RLC (Relative Lymphocyte Count), the low 
RLC group showed significantly greater progression to ESRD than the high RLC group 
(Kim and Kim, 2014) 
 
There is no association between high serum calcium (>9.8 mg/dL) and renal outcome 
since low serum calcium (<9.0 mg/dL) is an independent prognostic factors of rapid 
renal function progression in CKD stages 3–4 patients (Lim et al., 2014)  
 
2.3.3.5  Blood Urea Nitrogen (BUN)  
 
Increased blood urea nitrogen (BUN) is a helpful clinical clue for the diagnosis of 
prerenal azotemia, but other causes of unbalanced increment of BUN should be 
considered including high protein intake. Especially important in the elderly patients 
with underlying CKD and CHF (Shavit et al., 2012) . Among 260 of patients (17.3%), an 
increase in BUN 50% occurred in during hospital course, and was associated with 
increased risk of mortality after adjustments of clinical variables, eGFR and BUN on 
admission (HR, 1.7 95% CI 1.3–2.2; P < 0.0001) (Aronson et al., 2008). 
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2.3.4  Drug development in CKD 
 
Medications used are important among CKD patients which require consideration. 
Many drugs such as cimetidine and trimethoprim interfere with creatinine tubular 
secretion and thus raise serum creatinine levels. The result is a decrease in estimated 
GFR even though there has been no real effect on renal function. Likewise, unstable 
kidney function was leading to produce unreliable estimated GFRs, since a steady 
state must be achieved before the GFR can be estimated (Stevens et al., 2006). 
 
According to Hartmann et al. (2010), if the patient is in CKD stage 3 or higher with GFR 
is below 60 mL/min, certain drugs should no longer be given, either because they tend 
to damage the kidneys or because they are insufficiently eliminated by poorly 
functioning kidneys and will therefore accumulate in the body and cause toxic side 
effects on other organs. Three of the drugs were ACE inhibitors, AT1 blockers, and the 
renin inhibitor have renal dependent pharmacokinetics, so that it suffices to give these 
drugs in half the normal dose to patients with renal insufficiency, hence for this 
situation, special attention must be paid to the risk of hyperkalemia. (Hartmann et al., 
2010). Spironolactone should be given only in a low dose no or not at all, to patients 
with renal insufficiency to avoid hyperkalemia. A patient with renal insufficiency is 
given, then only in combination with a thiazide diuretic, furosemide, or both (Hartmann 
et al., 2010). 
 
Angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers 
(ARBs) are probably the first-choice antihypertensive, particularly if proteinuria is 
present as they are effective in delaying progression of diabetic and non-diabetic 
proteinuric nephropathy. Although ACEi and ARB therapy reduce proteinuria by 
reducing angiotensin II, this dilates the efferent arteriole and reduces intraglomerular 
pressure and GFR (Haynes and Winearls, 2010). 
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Moreover, a study from Haynes and Winearls (2010) stated that the anti-proteinuric 
effect of ACEi or ARB therapy is improved by sodium restriction and/or diuretic therapy. 
In the advanced stages of CKD, sodium retention contributes to hypertension and 
hence diuretic therapy when relatively with high doses can reduce blood pressure 
successfully. Patients with CKD frequently need multiple agents to control blood 
pressure.  
 
Systolic blood pressure was slightly higher in patients with CKD than in patients with 
normal eGFR. There was little change in systolic and diastolic blood pressure. There 
was a greater used of inhibitors of the renin-angiotensin system during the trial in 
patients with CKD where, 64.8% of patients receiving atorvastatin 80 mg and 66.0% of 
patients receiving atorvastatin 10 mg compared  than in patients with normal eGFR 
with  56.5% receiving atorvastatin 80 mg  and 59.4% receiving atorvastatin 10 mg 
(Shepherd et al., 2008). 
 
Lipid-lowering therapy is not widely used in persons with chronic kidney disease (CKD) 
regardless of a high burden of dyslipidemia and cardiovascular disease. This  therapy 
decreased cardiac death and atherosclerosis-mediated cardiovascular events in 
persons with CKD (Upadhyay et al., 2012). Furthermore, the lowering LDL cholesterol 
with the combination of simvastatin and ezetimibe safely reduces the risk of major 
atherosclerotic events in a wide range of patients with chronic kidney disease. Among 
the 6247 patients not on dialysis at randomisation, simvastatin plus ezetimibe did not 
produce significant reductions in any of the prespecified measures of renal disease 
progression: ESRD defined as commencement of maintenance dialysis or 
transplantation (RR 0·97, 95% CI 0·89–1·05, p=0·41); ESRD or death (RR 0·97, 0·90–
1·04, p=0·34); and ESRD or doubling of baseline creatinine (RR 0·93, 0·86–1·01; 
p=0·09) (Baigent et al., 2011) 
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2.4 Conceptual framework 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Socio-demographic: 
Age, gender, race, 
smoking status, alcohol 
status 
Comorbidity: 
Family history of diseases, 
patients comorbid: ( HPT, 
DM, HPL,SRD, PH, CVD, 
Gout, Anemia, SLE, HIV) 
Biochemical 
parameters: 
ABG, FBC, RFT, SDP, 
DBP, HCT 
Treatment 
characteristics : 
Concomitant medication 
 
Event 
CKD Patient with ESRD 
& received dialysis 
 
Censored 
-Patients not received 
dialysis 
-loss to follow up 
CKD 
Prognostic factors of 
renal survival 
Renal survival 
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CHAPTER 3 
 METHODOLOGY 
 
3.1 Study Design 
 
The study design applied in this study was a retrospective cohort study. Patients‟ 
medical records were reviewed from Medical Record Unit, Hospital USM. The 
advantage of this study design included typically requiring less time and these studies 
tend to be less expensive because the outcome and exposure had already occurred. 
 
3.2 Study Period 
 
The recruitment phase of the subjects began from year 1st January 2005 until 31st 
December 2015. The period of study was from September 2015 until April 2016. The 
data collection period was from February 2016 until April 2016. 
 
3.3  Study Location 
 
The study was conducted in the Hospital USM which is an urban, academic hospital 
and tertiary care center with specialist in nephrology. CKD Resource Centre HUSM 
have nephrology clinic, CKD research unit (Renal Lab), CKD Interventional Nephrology 
Unit, CKD education and training Unit and Hemodialysis Unit. 
 
3.4 Study Population 
3.4.1 Reference Population  
 
The reference population was all CKD patients in Kelantan 
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3.4.2 Source Population 
 
The source population was all CKD patients registered in Hospital USM, Kubang 
Kerian, Kelantan during the study period from 1st January 2005 until 31st December 
2015. 
 
3.4.3 Sampling Frame 
 
The sampling frame was a list of all CKD patients registered in Hospital USM from 1st 
January 2005 until 31st December 2015 that fulfill inclusion and exclusion criteria. 
3.4.3 (a)  Inclusion Criteria 
 
The inclusion criteria are all CKD patients who received dialysis registered in Hospital 
USM from 1st January 2005 until 31st December 2015. 
3.4.3 (b)  Exclusion Criteria 
 
The exclusion criteria CKD patients with more than 30% of missing data and patients 
who were transferred out from Hospital USM.  
 
 
 
 
 
 
 
